IMARC Group, a leading market research company, has recently releases report titled “Cholera Vaccine Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028.” The study provides a detailed analysis of the industry, including the global cholera vaccine market share, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
Report Highlights
How big is the cholera vaccine market?
The global cholera vaccines market size reached US$ 4.9 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 9.2 Million by 2028, exhibiting a growth rate (CAGR) of 11.1% during 2023-2028.
What are Cholera Vaccine?
Cholera vaccines are biological preparations that assist in strengthening the immune system and provide immunity against cholera. It also helps in minimizing the risk of bacterial infections that may spread through contaminated food and water and leads to abdominal pain, fever, rapid heart rate, loss of skin elasticity, low blood pressure, muscle cramps, and dry mucous membranes. At present, it includes the oral cholera vaccine (OCV) that protects against cholera for up to two years, and the injectable cholera vaccine (ICV), which facilitates prevention for six months.
Request Free Sample Copy of This Report: https://www.imarcgroup.com/cholera-vaccines-market/requestsample
What are the growth prospects and trends in the cholera vaccine industry?
The growing global population and increasing focus on prevention and control of cholera in areas with poor sanitation and hygiene currently represent one of the key factors positively influencing the market across the globe.
In addition, governments and private organizations are introducing favorable health initiatives for the prevention and control of infectious diseases like cholera. This, along with the growing awareness about the importance and effectiveness of cholera vaccines among the people, is creating a favorable market outlook.
Apart from this, increasing investments in research and development (R&D) activities for developing new vaccine formulations for cholera, including single-dose vaccines and heat-stable vaccines that do not require refrigeration, are stimulating the growth of the market around the world.
What is included in market segmentation?
The report has segmented the market into the following categories:
Breakup by Vaccine Type:
- Whole Cell V. Cholerae O1 with Recombinant B-Subunit
- Killed Oral O1 and O139
Breakup by Product:
- Dukoral
- Shanchol
- Vaxchora
- Euvichol and Euvichol-Plus
- Others
Breakup by End User:
- Hospitals and Clinics
- Research and Academic Laboratories
- Others
Market Breakup by Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
Who are the key players operating in the industry?
The report covers the major market players including:
Astellas Pharma Inc., Celldex Therapeutics Inc. (Avant Immunotherapeutics Inc.), Emergent BioSolutions Inc., Eubiologics Co. Ltd., Johnson & Johnson, Merck & Co. Inc, Pfizer Inc., PharmaChoice Canada Inc, Sanofi S.A., Takeda Pharmaceutical Company Limited and Valneva SE.
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC Group’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
USA: +1-631-791-1145 | Asia: +91-120-433-0800
Email: sales@imarcgroup.com
Follow us on Twitter: @imarcglobal
LinkedIn: https://www.linkedin.com/company/imarc-group/mycompany/
